Patients at risk will receive therapy with anidulafungin

Patients at risk will receive therapy with anidulafungin
Anidulafungin: Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards

Anidulafungin

Sex: Female, Male

Region of Enrollment

The main interest is to evaluate the ocurrence of candidemia in patients with negative 1,3 beta-D-glucan who discontinue anidulafungin

Evaluate the Ocurrence of Candidemia in Patients With Negative 1,3 Beta-D-glucan Who Discontinue Anidulafungin

Overall Study

Marcio Nucci

One Arm

Candidemia

Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards

Federal University of Rio de Janeiro

Negative Beta Glucan in ICU Patients

A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients

Universidade Federal do Rio de Janeiro

Hematologic Malignancies

standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.
Prophylaxis will be given until the recovery from neutropenia (ANC > 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture.

Elisabethinen hospital

Anidulafungin in Patients With Hematologic Malignancies

Anidulafungin in Patients With Hematologic Malignancies - An Open-label, Prospective Study to Evaluate the Safety Profile at Prophylactic and Therapeutic Dosages

candidiasis invasive/fever

Negative Beta Glucan in ICU Patients

Anidulafungin in Patients With Hematologic Malignancies

科学支持的最完整的草药数据库